GSK ends Alector alliance as both lead assets fail
GSK has ended its five-year neuroscience partnership with Alector after latozinemab and nivisnebart both failed. The post GSK ends Alector alliance as both lead assets fail appeared first on European Medical Journal .
European Medical Journal19h ago 
